目的：分析癌症患者化疗引起的不良反应/事件的临床特征，进一步探讨当归补血汤（DBD）对化疗所致骨髓抑制（BMS）的潜在机制。方法：回顾性收集和评估了2015年至2022年期间，某医院接受化疗药物引起不良反应/事件的患者的临床数据。根据不良反应/事件分析的结果，我们使用网络药理学探索了DBD对BMS的潜在机制。结果：151例患者（72.25%）出现单一化疗药物引起的不良反应/事件。此外，白金类药物产生了最多的不良影响。研究还发现，化疗引起了最多的BMS病例，包括白金类药物。因此，BMS是此部分化疗引起的最常见不良反应疾病。根据网络药理学的研究结果，DBD主要参与了1,510个主要靶点和19个关键活性成分，可以预防BMS。根据富集分析，PI3K-AKT、TNF、MAPK和IL-17信号通路是DBD抵抗BMS的主要通路。分子对接显示，DBD的主要活性成分当归素与BMS的关键靶点PTGS2具有最高的结合能力（-10.08 kJ mol-1）。结论：接受化疗的癌症患者有发展BMS的风险。在服药期间应进行定期血液检查，早期发现和治疗可以减少患者发生不良反应/事件的风险。此外，本研究证明了DBD通过多种靶点和通路可能在避免BMS方面具有重要作用。版权所有 © 2023 Yu, Yan, Zhu, Luo, Sohail, Ning and Xu.

Objective: To analyze the clinical characteristics of adverse reactions/events based on chemotherapy in cancer patients, and then explore the potential mechanism of Danggui Buxue Decoction (DBD) against chemotherapy-induced bone marrow suppression (BMS). Methods: Retrospectively collected and evaluated were the clinical data of patients in a hospital who experienced adverse reactions/events brought on by chemotherapeutic medications between 2015 and 2022. We explored the potential mechanism of DBD against BMS using network pharmacology based on the findings of the adverse reactions/events analysis. Results: 151 instances (72.25%) experienced adverse reactions/events from a single chemotherapy medication. Besides, platinum-based medications produced the most unfavorable effects. The study also found that chemotherapy caused the highest number of cases of BMS, including platinum drugs. Consequently, BMS is the most prevalent adverse reaction disease caused by chemotherapy found in this part. According to network pharmacology findings, DBD can prevent BMS primarily involving 1,510 primary targets and 19 key active ingredients. Based on the enrichment analysis, PI3K-AKT, TNF, MAPK, and IL-17 signaling pathways made up the majority of the DBD-resisting BMS pathways. Molecular docking displayed that kaempferol, the major active ingredient of DBD, had the highest binding energy (-10.08 kJ mol-1) with PTGS2 (a key target of BMS). Conclusion: Cancer patients who received chemotherapy had a risk to develop BMS. Regular blood tests should be performed while taking medicine; early discovery and treatment can reduce a patient's risk of experiencing adverse reactions/events. Additionally, this study demonstrated that DBD, through a variety of targets and pathways, may be crucial in avoiding BMS.Copyright © 2023 Yu, Yan, Zhu, Luo, Sohail, Ning and Xu.